TERN-501, a THRβ agonist, significantly reduced liver fat in a dose-dependent manner over 12 weeks in patients with MASH. Compared to placebo, MRI-PDFF and cT1 reductions were substantial, and significantly more participants receiving TERN-501 achieved a clinically significant change in cT1 by 6 weeks.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?